請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52005
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 葉秀慧(Shiou-Hwei Yeh) | |
dc.contributor.author | Ting-Yu Gu | en |
dc.contributor.author | 顧庭宇 | zh_TW |
dc.date.accessioned | 2021-06-15T14:02:34Z | - |
dc.date.available | 2025-09-01 | |
dc.date.copyright | 2015-09-25 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-20 | |
dc.identifier.citation | 1. Arzumanyan, A., H.M. Reis, and M.A. Feitelson, Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer, 2013. 13(2): p. 123-35. 2. Nijhara, R., et al., Sustained activation of mitogen-activated protein kinases and activator protein 1 by the hepatitis B virus X protein in mouse hepatocytes in vivo. J Virol, 2001. 75(21): p. 10348-58. 3. Ueda, H., et al., Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet, 1995. 9(1): p. 41-7. 4. Caselmann, W.H., Transactivation of cellular gene expression by hepatitis B viral proteins: a possible molecular mechanism of hepatocarcinogenesis. J Hepatol, 1995. 22(1 Suppl): p. 34-7. 5. Kim, C.M., et al., HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature, 1991. 351(6324): p. 317-20. 6. Yu, D.Y., et al., Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J Hepatol, 1999. 31(1): p. 123-32. 7. Lozano, R., et al., Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet, 2012. 380(9859): p. 2095-2128. 8. Yang, J.D. and L.R. Roberts, Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol, 2010. 7(8): p. 448-58. 9. Yu, M.-W., et al., Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men. Journal of the National Cancer Institute, 2005. 97(4): p. 265-272. 10. Center, M.M. and A. Jemal, International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev, 2011. 20(11): p. 2362-8. 11. McGlynn, K.A. and W.T. London, The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis, 2011. 15(2): p. 223-43, vii-x. 12. Lu, S.N., et al., Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer, 2006. 119(8): p. 1946-52. 13. Yu, M.-W., et al., Androgen-Receptor Gene CAG Repeats, Plasma Testosterone Levels, and Risk of Hepatitis B-Related Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2000. 92(24): p. 2023-2028. 14. Yang, W.J., et al., Hepatitis B virus X protein enhances the transcriptional activity of the androgen receptor through c-Src and glycogen synthase kinase-3beta kinase pathways. Hepatology, 2009. 49(5): p. 1515-24. 15. Chiu, C.M., et al., Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. Proceedings of the National Academy of Sciences of the United States of America, 2007. 104(8): p. 2571-8. 16. Chen, P.J., et al., Androgen pathway stimulates microRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis. Hepatology, 2012. 56(2): p. 632-43. 17. Wang, S.H., et al., Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology, 2009. 50(5): p. 1392-402. 18. Faris, J.E. and M.R. Smith, Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Current Opinion in Endocrinology, Diabetes and Obesity, 2010. 17(3): p. 240-246. 19. Lin, H.-Y., et al., Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology, 2008. 47(6): p. 1924-1935. 20. Samuel, V.T., et al., Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease. Journal of Biological Chemistry, 2004. 279(31): p. 32345-32353. 21. Wang, J., et al., Overfeeding Rapidly Induces Leptin and Insulin Resistance. Diabetes, 2001. 50(12): p. 2786-2791. 22. Nakae, J., et al., The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. Journal of Clinical Investigation, 2001. 108(9): p. 1359. 23. Puigserver, P., et al., Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction. Nature, 2003. 423(6939): p. 550-555. 24. Matsumoto, M., et al., Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell metabolism, 2007. 6(3): p. 208-216. 25. Haeusler, R.A., K.H. Kaestner, and D. Accili, FoxOs function synergistically to promote glucose production. Journal of Biological Chemistry, 2010. 285(46): p. 35245-35248. 26. Li, S., M.S. Brown, and J.L. Goldstein, Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proceedings of the National Academy of Sciences, 2010. 107(8): p. 3441-3446. 27. Maxfield, F.R. and T.E. McGraw, Endocytic recycling. Nat Rev Mol Cell Biol, 2004. 5(2): p. 121-132. 28. Nathan, J.D., et al., Impaired hepatocyte glucose transport protein (GLUT2) internalization in chronic pancreatitis. Pancreas, 2001. 22(2): p. 172-8. 29. Knutson, V.P., Cellular trafficking and processing of the insulin receptor. The FASEB Journal, 1991. 5(8): p. 2130-8. 30. Krupp, M. and M.D. Lane, On the mechanism of ligand-induced down-regulation of insulin receptor level in the liver cell. J Biol Chem, 1981. 256(4): p. 1689-94. 31. Asante-Appiah, E. and B.P. Kennedy, Protein tyrosine phosphatases: the quest for negative regulators of insulin action. Vol. 284. 2003. E663-E670. 32. Owen, C., et al., Inducible liver-specific knockdown of protein tyrosine phosphatase 1B improves glucose and lipid homeostasis in adult mice. Diabetologia, 2013. 56(10): p. 2286-2296. 33. Agouni, A., et al., Liver-specific deletion of protein tyrosine phosphatase (PTP) 1B improves obesity- and pharmacologically induced endoplasmic reticulum stress. Biochem J, 2011. 438(2): p. 369-78. 34. Bence, K.K., Hepatic PTP1B Deficiency: The Promise of a Treatment for Metabolic Syndrome? Journal of clinical metabolism diabetes, 2010. 1(1): p. 27-33. 35. Delibegovic, M., et al., Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes, 2009. 58(3): p. 590-9. 36. Xu, E., M. Schwab, and A. Marette, Role of protein tyrosine phosphatases in the modulation of insulin signaling and their implication in the pathogenesis of obesity-linked insulin resistance. Reviews in Endocrine and Metabolic Disorders, 2014. 15(1): p. 79-97. 37. Tiganis, T., PTP1B and TCPTP – nonredundant phosphatases in insulin signaling and glucose homeostasis. FEBS Journal, 2013. 280(2): p. 445-458. 38. Stuible, M. and M.L. Tremblay, In control at the ER: PTP1B and the down-regulation of RTKs by dephosphorylation and endocytosis. Trends in Cell Biology, 2010. 20(11): p. 672-679. 39. Tao, J., C.C. Malbon, and H.-y. Wang, Insulin Stimulates Tyrosine Phosphorylation and Inactivation of Protein-tyrosine Phosphatase 1B in Vivo. Journal of Biological Chemistry, 2001. 276(31): p. 29520-29525. 40. Dadke, S., A. Kusari, and J. Kusari, Phosphorylation and activation of protein tyrosine phosphatase (PTP) 1B by insulin receptor. Molecular and cellular biochemistry, 2001. 221(1-2): p. 147-154. 41. Bandyopadhyay, D., et al., Protein-Tyrosine Phosphatase 1B Complexes with the Insulin Receptor in Vivo and Is Tyrosine-phosphorylated in the Presence of Insulin. Journal of Biological Chemistry, 1997. 272(3): p. 1639-1645. 42. Ravichandran, L.V., et al., Phosphorylation of PTP1B at Ser50 by Akt Impairs Its Ability to Dephosphorylate the Insulin Receptor. Molecular Endocrinology, 2001. 15(10): p. 1768-1780. 43. Yip, S.-C., S. Saha, and J. Chernoff, PTP1B: a double agent in metabolism and oncogenesis. Trends in Biochemical Sciences, 2010. 35(8): p. 442-449. 44. Barone, M., et al., Possible involvement of androgen receptor alterations in hepatocarcinogenesis. Dig Liver Dis, 2009. 41(9): p. 665-70. 45. Wu, M.-H., et al., Androgen Receptor Promotes Hepatitis B Virus–Induced Hepatocarcinogenesis Through Modulation of Hepatitis B Virus RNA Transcription. Science Translational Medicine, 2010. 2(32): p. 32ra35. 46. Huang, Y.H., et al., A murine model of hepatitis B-associated hepatocellular carcinoma generated by adeno-associated virus-mediated gene delivery. Int J Oncol, 2011. 39(6): p. 1511-9. 47. Wu, K.K. and Y. Huan, Streptozotocin-Induced Diabetic Models in Mice and Rats, in Current Protocols in Pharmacology. 2008, John Wiley Sons, Inc. 48. Liu, Y., et al., A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature, 2008. 456(7219): p. 269-73. 49. Chiang, C.H., et al., Association between obesity, hypertriglyceridemia and low hepatitis B viral load. Int J Obes, 2013. 37(3): p. 410-415. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52005 | - |
dc.description.abstract | B肝病毒(Hepatitis B Virus, HBV)慢性感染引起之肝細胞癌 (Hepatocellular carcinoma, HCC),是台灣重要的癌症死因。自慢性感染階段開始,B肝病毒造成的相關疾病皆好發於男性,根據本實驗室過往之研究,好發於男性可能是由於男性病患特有之雄性激素路徑的影響。受雄性激素活化的肝臟雄性激素受體(Androgen receptor, AR)能透過B肝病毒的Enhancer I區域上Androgen-responsive element序列,加強病毒轉錄與複製;而B肝病毒也能藉由非結構蛋白質HBx增強AR的轉錄活性。此病毒與雄性激素路徑間的互相影響,是造成男性病患較高之病毒量以及較高之肝癌風險之主因。然而由於生理狀態下男性肝臟AR表現量極低,本論文因此提出一假說,即B肝病毒不只能增強AR的活性,更能調控AR表現量,來建立於肝細胞中HBx與AR之間的正回饋作用。 為了探討此假說之可能性,我們使用B肝病毒基因轉殖鼠動物模式,比較之下發現轉殖鼠之肝臟中AR表現量在禁食情況下確實有增加的現象。進一步利用此小鼠動物模式探討其分子機制,將小鼠進行去勢以抑制雄性激素合成,更發現調控機制可能與雄性激素活性有關。雄性激素抑制AR之表現量,而B肝病毒基因之轉殖會造成與去勢類似之作用。本論文實驗結果同時指出B肝病毒有可能藉由增加胰島素路徑之活性造成對AR表現之影響。有鑑於利用磷酸酶對胰島素受體進行去磷酸化,為細胞調控胰島素路徑的機制之一,本論文因而探究B肝病毒是否藉由特定磷酸酶影響胰島素路徑之可能性,初步結果顯示胰島素路徑之增加與PTP1B磷酸酶之磷酸化相關,此初步結果仍需進一步實驗以探究其對維持AR較高之表現量之重要性。本論文的發現將有助於釐清B肝病毒在調控AR轉錄活性之前,究竟是如何增加AR表現量,以建立後續更有效率的病毒複製之分子機制。 | zh_TW |
dc.description.abstract | There exists a gender difference in the incidence of hepatitis B virus (HBV)-related HCC, starting from the chronic hepatitis stage, which leads to a higher risk to HCC in men than in women. Our previous studies demonstrated that this male predominance could be attributed to the androgen pathway. The androgen activated androgen receptor (AR) can promote HBV transcription via binding to the androgen-responsive elements (AREs) located in the HBV enhancer I region. The HBV X protein (HBx) can in turn enhance the transcriptional activity of AR. The interaction between HBx and AR leads to the higher HBV titer and a higher risk to HCC in men. Regarding to the very low AR protein level in normal male liver, this study was proposed to test if HBV infection could also increase the level of hepatic AR to further enhance this HBx-AR loop in male liver. We proposed to test this hypothesis in the HBV-transgenic (HBV-Tg) mouse model. We found that the AR protein was significantly higher in HBV-Tg than in control wild type male mice under fasting, similar as that caused by castration. Meanwhile, an increase of insulin pathway activity was identified both in HBV-Tg mice and in castrated wild type male mice under fasting. Our preliminary results further showed an association of increased IR phosphorylation with the phosphorylation of protein tyrosine phosphatase 1B (PTP1B). The critical role of this phosphorylation in regulating the elevation of hepatic AR is worthy to be further investigated. We expect the results can help clarify if HBV infection can stimulate the activity of androgen pathway through increasing both the expression level and the transcription activity of AR. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T14:02:34Z (GMT). No. of bitstreams: 1 ntu-104-R02445126-1.pdf: 2219070 bytes, checksum: 44894cbb747ea8bc9904d78234a5e88d (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 口試委員會審定書 I 謝辭 II 目錄 III 摘要 V Abstract VI 序言 1 B型肝炎病毒與B型肝炎 1 B型肝炎病毒引起之肝癌好發男性與雄性激素路徑相關 2 B肝病毒感染與雄性激素受體間之交互作用增加肝癌之風險 2 正常肝臟中雄性激素與其受體對新陳代謝之影響 3 肝臟中胰島素訊息傳遞路徑之活化及去活化調控 4 研究目的 7 材料與方法 8 實驗小鼠 8 動物操作 8 胰島素注射 8 胰島素去除 (Insulin depletion) 9 胰島素定量 9 蛋白質萃取 9 蛋白質定量 10 SDS-PAGE膠體電泳 10 免疫轉漬 10 鹼性磷酸酶處理 (Calf Intestinal Alkaline Phosphatase assay, CIP) 11 反轉錄定量聚合酶連鎖反應 (Quantitative reverse transcription-PCR) 11 結果 13 雄性B肝基因轉殖小鼠在禁食情況下肝臟內雄性激素受體表現量比對照組小鼠為高 13 去勢讓野生型小鼠肝臟組織裡AR表現量增加 13 B肝病毒可能藉由調控胰島素路徑增加AR的表現量 14 胰島素路徑的確因為去勢及B肝病毒而活化 15 雄性激素路徑可能藉由調控PTP1B之磷酸化影響其活性,抑制胰島素路徑活性 15 AR表現量於禁食四到六小時間開始減少,血液中胰島素同樣位於低點 16 去除胰島素,AR表現量明顯降低 17 討論 18 雄性激素與AR調控於肝臟可能之生理意義 18 AR是否影響胰島素路徑之去活化 19 胰島素路徑調控AR表現量 19 B肝病毒調控AR表現量與胰島素路徑之關聯 20 圖表附錄 21 參考文獻 29 | |
dc.language.iso | zh-TW | |
dc.title | B型肝炎病毒調控雄性激素受體表現量之機制研究 | zh_TW |
dc.title | The mechanism for Hepatitis B virus to increase the expression of hepatic androgen receptor | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳培哲(Pei-Jer Chen),董馨蓮(Shin-Lian Doong) | |
dc.subject.keyword | B型肝炎病毒,雄性激素,雄性激素受體,胰島素路徑, | zh_TW |
dc.subject.keyword | Hepatitis B virus,Androgen,Androgen receptor,insulin pathway, | en |
dc.relation.page | 32 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-08-20 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 2.17 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。